Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 9/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2399053 | 0.94 | MAPT (0.52) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL27587862 | 0.92 | MAPT (0.55) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL241757 | 0.86 | ALDH1A1 (0.48) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| Fosfonet SCHEMBL8768084 | 0.86 | MEN1 (0.45) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| Hydrochloric Acid SCHEMBL22775406 | 0.84 | ALDH1A1 (0.47) | ALDH1A1TBXAS1LMNAFFAR1 | |
| SCHEMBL2431568 | 0.83 | SMN1; SMN2 (0.40) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL28715305 | 0.82 | F7 (0.50) | ALDH1A1ALOX15MAPTCYP1A2CYP2C19 | |
| SCHEMBL23869882 | 0.81 | SMN1; SMN2 (0.43) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL28873885 | 0.81 | HDAC3 (0.45) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL18381295 | 0.79 | SMN1; SMN2 (0.56) | SMN1; SMN2HDAC3HDAC4HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0654035-B1 | PHOSPHONOACETIC ESTERS AND ACIDS AS ANTI-INFLAMMATORIES | UPJOHN CO (US) | 1997-08-20 | — | — | EP | claimed |
| US-5565441-A | AN N-HETEROCYCLE DERIVATIVE; ANTIARTHRITIC AGENTS; DISEASES CHARACTERIZED BY ABNORMAL PHOSPHATE AND CALCIUM METABOLISM; CHRONIC DISEASES | THE UPJOHN COMPANY (US) | 1996-10-15 | — | — | US | claimed |
| EP-0654035-A1 | PHOSPHONOACETIC ESTERS AND ACIDS AS ANTI-INFLAMMATORIES. | UPJOHN CO (US) | 1995-05-24 | — | — | EP | claimed |
| WO-1994003463-A1 | PHOSPHONOACETIC ESTERS AND ACIDS AS ANTI-INFLAMMATORIES | THE UPJOHN COMPANY (US) | 1994-02-17 | — | — | WO | claimed |
| US-20090131384-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS | SYNDEXA PHARMACEUTICALS CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131384-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS | SYNDEXA PHARMACEUTICALS CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| EP-1646383-A4 | DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR | BETHESDA PHARMACEUTICALS INC (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2009007418-A1 | NOVEL BRONCHODILATING ISOQUINOLINE AMIDES | RESPIRATORIUS AB (SE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007418-A1 | NOVEL BRONCHODILATING ISOQUINOLINE AMIDES | RESPIRATORIUS AB (SE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2007111994-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS | SYNDEXA PHARMACEUTICALS CORPORATION (US) | 2007-10-04 | — | — | WO | disclosed |
| EP-1646383-A1 | DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR | Bethesda Pharmaceuticals, Inc. (US) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005009437-A1 | DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR | BETHESDA PHARMACEUTICALS, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2002076177-A2 | DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR | BETHESDA PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| EP-0654035-B1 | PHOSPHONOACETIC ESTERS AND ACIDS AS ANTI-INFLAMMATORIES | UPJOHN CO (US) | 1997-08-20 | — | — | EP | disclosed |
| US-5643895-A | Phosphonoacetic esters and acids as anti-inflammatories | THE UPJOHN COMPANY (US) | 1997-07-01 | — | — | US | disclosed |
| US-5565441-A | AN N-HETEROCYCLE DERIVATIVE; ANTIARTHRITIC AGENTS; DISEASES CHARACTERIZED BY ABNORMAL PHOSPHATE AND CALCIUM METABOLISM; CHRONIC DISEASES | THE UPJOHN COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0654035-A1 | PHOSPHONOACETIC ESTERS AND ACIDS AS ANTI-INFLAMMATORIES. | UPJOHN CO (US) | 1995-05-24 | — | — | EP | disclosed |
| WO-1994003463-A1 | PHOSPHONOACETIC ESTERS AND ACIDS AS ANTI-INFLAMMATORIES | THE UPJOHN COMPANY (US) | 1994-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131384-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS | NR1H3, NR1H2, SREBF1 | SMN1; SMN2 4422/4885HDAC3 255/4885MAPK1 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.